Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antisoma has announced new preclinical data of its anti-nucleolin aptamer drug AS1411, which showed that the drug killed cells from a variety of blood cancer cell lines, including leukaemias, lymphomas and a myeloma.
Subscribe to our email newsletter
In further experiments, these lines were treated with a combination of AS1411 and doxorubicin, a drug often used to treat Burkitt’s lymphoma. The AS1411-doxorubicin combination produced synergistic (more than additive) killing of the lymphoma cells.
Positive combination data have also been obtained in AML (acute myeloid leukaemia) cell lines. Here, AS1411 was combined with cytarabine, a drug widely used in AML. A Phase II trial is now evaluating the combination of AS1411 and cytarabine in AML patients.
Fiona McLaughlin, director of Research at Antisoma, said: “These new data provide further support for our AS1411-cytarabine combination trial in AML, and also illustrate the broader potential of AS1411 against a range of haematological malignancies.”